| Biomarker ID | 1908 |
| PMID | 30401717 |
| Year | 2019 |
| Biomarker | ADAM12; AURKA; AURKB; C7orf49; CDCA8; CENPF; CIT; DNMT3B; DYRK2; FANCD2; FGD1; GDAP1; GPI; GTSE1; HNRNPUL1; IPO9; KIF23; LIG1; NCAPH; NHSL1; PEG10; SKP2; TMEM65; TOP2A; TPX2; UBE2T; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Agressive PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include (TPX2): Polo-like kinase 1 (PLK1) pathway, Ran role in mitotic spindle regulation |
| Experiment | Primary Prostate Cancer Vs Metastatic Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | 491 patients with primary Prostate cancer and 1 with metastatic prostate cancer was used from the TCGA cohort. Results were validated on GEO cohort: GSE21034. Results shown here are for GEO cohort |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | RNA-Seq |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |